~//bj.watch/overview
live

Latest signal

last curated pass Oct 29, 2026 · 8 public entries · source-aware summaries from 6 legacy curated cards plus llm-wiki tweets

# all # health # longevity # nutrition # sleep # concepts

Recent curated signals

Research claim “Young adults having strokes increasingly have the bodies of 60 yr olds”: the stroke relay’s core figure verifies exactly — a 50% relative jump in 3+ cardiovascular risk factors among 18–35-year-old stroke patients over eight years — but the “new study” is a 19-month-old Florida registry analysis, and “bodies of 60 yr olds” is gloss the paper does not make Johnson posted the feed’s first stroke-relay post: “Strokes in young people used to be considered freak events. A new study found that young adults having strokes increasingly have the bodies of 60 yr olds. In stroke patients aged 18–35, those with 3+ major cardiovascular warning signs jumped by 50% in eight years. The culprits: high blood pressure, high cholesterol, obesity, and smoking.” (350 likes, 20 reposts, 56 replies; October 29, 21:04 UTC, with an attached figure). The core figure verifies with unusual precision: “Temporal Trends in Vascular Risk Factor Burden Among Young Adults With Ischemic Stroke — The Florida Stroke Registry,” Neurology, March 25, 2025 (10.1212/WNL.0000000000213447), analyzed 36,488 Get With the Guidelines-Stroke ischemic-stroke patients (January 2014–December 2022), 3,363 of them aged 18–35, and found polymorbidity — 3 or more of nine vascular risk factors, a list that includes exactly the post’s hypertension, dyslipidemia, obesity, and smoking — rose from 10.9% to 16.4% in the 18–35 group (p=0.002), a 50.4% relative increase over exactly eight years (the 36–55 group rose 34.6%→41.9% over the same span). The boundaries the post drops: the figure is the share of already-hospitalized stroke patients carrying 3+ factors, not population stroke risk; the jump is relative — 5.5 percentage points absolute; a Florida stroke-registry hospital cohort is not a population sample; “a new study” is 19 months old (published March 2025) and unnamed in the post; “bodies of 60 yr olds” is gloss — the paper measures risk-factor counts, not biological age or “body age”; and rising risk-factor prevalence among young stroke patients is association with the documented incidence rise, not a demonstrated cause. The dashboard records an attributed research relay with a verified core figure and aged-up framing — not evidence about any individual reader’s stroke risk, a screening recommendation, or medical advice. Research claim “Avoid eating dirty during an acute immune reaction”: the relay traces to a Nature mouse study published one day before the post — four days of high-fat food at inflammation onset primed skin for exaggerated recurrences 6.5 months later — but “permanently,” “immune cells” at large, and the viral/autoimmune/tissue-injury list all outrun the paper Johnson posted the feed’s first diet-timing immunology directive: “Avoid eating dirty during an acute immune reaction bc it can permanently lock in how immune cells react in the future. *viral infection, autoimmune flare, tissue injury…” (1,473 likes, 64 reposts, 58 replies; October 29, 19:52 UTC, with an attached figure). The relay traces to a brand-new paper: Jiang, Tayeri, … Bapat, “Diet at disease onset determines tissue inflammatory memory,” Nature, published October 28, 2026 (10.1038/s41586-026-11181-4) — one day before the post — covered by UCSF’s same-week news release. The verified core: in mice, transient high-fat feeding confined to a 4-day peri-initiation window amplified imiquimod-induced type-17 skin inflammation in lean animals to severity comparable with chronic obesity (~2.1-fold ear thickening after just one week of the diet); the same fat load outside the window had no impact, and switching obese mice to low-fat food during the window blunted the amplification. After recovery and return to low-fat food, a chromatin-poised tissue-resident memory CD4+ T-cell population persisted in previously inflamed skin, and rechallenges stayed exaggerated out to 6.5 months — an effect transplantable with the skin patch itself, abolished by NLRP3 inhibition during the initial flare or by CD4 depletion, and mirrored acutely in the lung. The boundaries the post drops: this is mice and a psoriasis-like cream model; the memory is tissue-local — only previously inflamed ears overreacted, not the contralateral ear or the whole animal; durable to 6.5 months is not “permanent”; “how immune cells react” in general overstates a skin CD4+ T_RM population; the “viral infection, autoimmune flare, tissue injury” list extends the finding to triggers the paper did not test; the corresponding author’s own caution is that a laboratory mouse diet “doesn’t map neatly onto what we eat”; and the post names no study. The dashboard records an attributed research relay with a verified one-day-old paper and expanded framing — not a reader eating-during-illness protocol, evidence about any human disease course, or medical advice. Sleep “We hung out in the dark and it was so much better”: the stage-lights anecdote is the feed’s second evidence-aligned sleep post in two days — the direction verifies against the canonical blue-light RCT, but the post itself is an unmeasured N=1 event story Johnson posted an event anecdote: “The lights pointing at the stage were blasting my eyeballs with blue light which makes it harder to fall asleep and fragments sleep. / So we hung out in the dark and it was so much better.” (761 likes, 7 reposts, 73 replies; October 28, 12:47 UTC). The mechanism direction is among the best-replicated findings in sleep research: in the canonical 5-night randomized crossover, reading a light-emitting e-book before bed versus a print book suppressed evening melatonin by 55.12%, delayed dim-light melatonin onset by more than 1.5 hours, lengthened sleep latency by roughly 10 minutes (25.65 vs 15.75 minutes), reduced REM sleep, and left readers sleepier the next morning (Chang, Aeschbach, Duffy, Czeisler, PNAS 2015, 10.1073/pnas.1418490112) — with the device spectrum peaking at 452 nm in the blue range the post names. The boundaries the post drops: the laboratory exposed participants at controlled illuminance for fixed durations, while the post is an unmeasured single-evening story — no lux reading, no exposure duration, no sleep data, and “so much better” is a subjective impression; the post names no study; and evening-light avoidance is general sleep hygiene, which the AASM suggests against as a stand-alone therapy for chronic insomnia disorder (Edinger et al., J Clin Sleep Med 2021, 10.5664/jcsm.8988). The dashboard records an attributed anecdote with a well-verified direction — not a measured result, a reader light-exposure protocol, or medical advice. Research claim “Slowing aging after the age 50 can add 3.6 yrs of life and is worth $4 million”: the relay traces to a real three-week-old modeling paper — the lifespan figure verifies as a round-up, and the money figure is a willingness-to-pay construct the post inflates and converts to cash-sounding dollars Johnson posted: “Slowing aging after the age 50 can add 3.6 yrs of life and is worth $4 million in economic value” (437 likes, 15 reposts, 56 replies; October 28, 14:01 UTC), with an attached chart screenshot OCR-identified as Felizzi, “Economic impact of biomarker-based aging interventions on healthcare costs and individual value,” Frontiers in Genetics, published October 11, 2026 (10.3389/fgene.2026.1814599). The paper is real and the relay is close: a single-author Hypothesis & Theory modeling study by an enGene (Basel) industry author that chains the DunedinPACE epigenetic clock (via Mak et al. 2023 frailty coupling, 10.1093/gerona/glad251) to Swiss-calibrated survival, frailty-prevalence, and healthcare-cost data, simulating three intervention scenarios starting at age 50. The lifespan figure verifies as a round-up: the most optimistic scenario (CR2, interventions assumed to hold the pace of aging at 1.0) yields a 3.58-year life-expectancy gain — the moderate scenario (CR1) gives 2.89. The money figure drifts twice. First, the paper’s most optimistic total individual value is CHF 3,236,195 — roughly $3.5–3.6 million at recent exchange rates, so “$4 million” overstates the paper’s own headline by about a tenth. Second, and larger: that figure is a willingness-to-pay construct — CHF 1,216,186 survival value plus CHF 2,020,009 health-quality value, undiscounted, in the Murphy–Topel/Scott value-of-life framework — a welfare measure of what a person would rationally pay for the assumed health and longevity gains, not cash, income, or savings. The modeled healthcare-system savings are CHF 131,608 per person over 40 years, and the paper itself reports the healthcare case becomes cost-sensitive once CHF 600 twice-yearly DunedinPACE testing is included, while the individual-value case stays positive. Boundaries the post drops: CR2 assumes an intervention can hold biological aging pace at 1.0 — assumed, not demonstrated by any available treatment; DunedinPACE captures one DNA-methylation axis of aging by the paper’s own caveat; costs and life tables are Swiss; the author is a longevity-industry employee framing the work explicitly around consumer business models; and the post names no study. The dashboard records an attributed research relay with a verified paper, a rounded lifespan figure, and a converted, inflated value construct — not evidence that any available intervention adds 3.6 years of life, a wealth or savings figure, or medical advice. N=1 test “I got mine to zero. The first documented case”: the feed’s semen-microplastics relay verifies study-for-study — the UNM testis and 113-man China semen papers are real and quoted closely — while the “first documented case” of zero is an unreplicated, specialty-lab N=1 with no published method Johnson posted the feed’s most detailed microplastics relay yet, quote-posting his own May 7, 2026 “I HAVE NO MICROPLASTICS IN MY BALLS” post: “Up to 100% of men have microplastics in their semen / I got mine to zero. The first documented case. / A 2024 study detected microplastics in 100% of human and dog testicular tissue. / In another study, microplastics were detected in the semen and urine of all of 113 tested men from China. / Researchers broke down plastic type and how they affected sperm quality. / The most common came from packaging (polystyrene, polypropylene, and polyethylene). / PTFE, the synthetic polymer used in non-stick Teflon pans, proved the most lethal, creating 11% lower sperm concentration and 9% fewer total sperm. / Ten studies have measured microplastics in human semen. Five found 100% detection. / The rest from 84% down to 37%, but older tests used standard infrared microscopes that are blind to particles smaller than 10–20 microns. Newer studies used Raman spectroscopy, which can spot particles down to 1 micron. / So in short, 100% prevalence is plausible if not likely.” (1,428 likes, 65 reposts, 104 replies; October 27, 17:37 UTC). Both named studies verify precisely. First: Hu, Garcia, Nihart, Campen et al., “Microplastic presence in dog and human testis…,” Toxicological Sciences, August 2024 (10.1093/toxsci/kfae060) — pyrolysis-GC/MS found microplastics in all 47 canine and all 23 human testes (human mean 328.44 µg/g, PE dominant), exactly “100% of human and dog testicular tissue,” with the authors’ own caveats that postmortem samples “typically did not experience a natural death,” the method is still being refined, and associations “do not imply causality.” Second: “Association of mixed exposure to microplastics with sperm dysfunction: a multi-site study in China,” eBioMedicine, July 2024 (10.1016/j.ebiom.2024.105369) — Raman microscopy on 113 men recruited at three reproductive-medicine centers found microplastics in all semen and urine samples (typically 3–5 polymer types; PS/PP/PE most detected, matching “most common came from packaging”), and PTFE-exposed participants showed lower sperm concentration (52.13 vs 58.32 million/mL, p=0.041 — the post’s “11% lower” is 10.6% rounded) and total sperm count (188.90 vs 207.67 million — the post’s “9% fewer”), with logistic-regression OR 4.32 for reduced concentration; the authors’ stated limits: cross-sectional, association not causation, no exposure concentrations, and a fertility-clinic population. The “ten studies / five at 100%” tally is consistent with the published semen-MP literature (100% cohorts: the 36-man Jinan general-population Raman study, Sci Total Environ 2024; the 113-man eBioMedicine study; a 115-man Malaysian Raman cohort detected MPs in all samples) and with detection-frequency reviews noting older FTIR/LD-IR work at lower rates (Zhao et al. 2023: 11/25; MDPI Toxics 2025: 34/45 = 75.6%; Tagliabue et al. 10.1016/j.scitotenv.2023.165922: 6/10) — though Johnson’s exact “84% down to 37%” endpoints match no single published tally we could identify, and his “Raman spots particles down to 1 micron” compresses that Raman resolves sub-micron in principle while real-world bio-matrix protocols vary. The boundaries the relay drops: his own zero result is a self-reported specialty-lab test with no published method, no third-party replication, and no pre-registration — in his own reply he concedes “This test is not widely available, sadly. I had a specialty lab create the test for me and conduct the analysis. It would be great if someone made a test widely available” (60 likes; 17:56 UTC) — so “first documented case” means first self-reported case; the underlying studies are cross-sectional associations in fertility-clinic or postmortem populations, not dose-response evidence that Teflon pans lower sperm counts in readers; and microplastics methodology reviews (Arch Toxicol 2026, 10.1007/s00204-026-04392-1) flag unstandardized nomenclature, small samples, and contamination risk across the whole field, which cuts at “zero” and “100%” claims alike. The dashboard records an attributed research relay with two verified studies and an unreplicated N=1 centerpiece—not evidence that non-stick pans harm readers’ fertility, a validated zero-microplastics protocol, a reader testing recommendation, or medical advice. Measurement “My body is indistinguishable from an elite athlete”: the twice-yearly MRI readout returns with 20s-equivalent fat and heart scores — self-reported scan impressions, a radiologist quote converted into a radiologist “report,” and the ACR still does not recommend whole-body MRI screening for asymptomatic people Johnson posted his twice-yearly MRI results with an attached report image: “my twice yearly mri results / > subcutaneous and visceral fat - 20s equivalent / > heart 100% score - 20s equivalent / > hippocampal occupancy - 99th percentile / radiologist report: / > my body is indistinguishable from an elite athlete / healthy bodies... / > make more money / > have more sex / > are more fun” (303 likes, 7 reposts, 50 replies; October 27, 21:55 UTC), following up a minute later that “mri scan was done with @prenuvo” (14 likes). The scanner and cadence are consistent with his established disclosure pattern: Prenuvo is the direct-to-consumer whole-body MRI company whose scans he has attributed his imaging to since his public protocol records, and “twice yearly” matches the twice-a-year cadence he has referenced since mid-2025. But the numbers are his summary of a private report he has not published: “20s equivalent” fat and heart scores, a “100%” heart score, and “99th percentile” hippocampal occupancy name no reference cohort, no normative dataset, and no scoring method — the same undisclosed-cohort pattern the dashboard has recorded on every percentile stack (“I am 18,” the Kernel brain-scan percentiles, the October 22 “you look your age” comeback). The line “radiologist report: my body is indistinguishable from an elite athlete” upgrades a quoted verbal impression to the status of a document, and the “healthy bodies make more money / have more sex / are more fun” coda is the same status pitch the feed attached to the October 22 percentile post. The context the post omits: no professional body recommends whole-body MRI screening of asymptomatic people — the American College of Radiology “does not believe there is sufficient evidence to justify recommending total body screening for patients with no clinical symptoms, risk factors or a family history” (ACR statement, April 17, 2023), RANZCR does not recommend it (position statement, July 2025), and the largest systematic review (J Magn Reson Imaging 2019, 10.1002/jmri.26736; 12 studies, 5,373 asymptomatic adults) found a pooled 32.1% prevalence of critical-or-indeterminate incidental findings with a substantial false-positive proportion (16.0% pooled) and no long-term verification of negative scans — the incidentaloma-and-overdiagnosis trade a screening-adjacent post never mentions. The boundaries: all figures are self-reported impressions of an unpublished report; “indistinguishable from an elite athlete” is an attributed quote, not a clinical finding; the scan was paid consumer screening, not a diagnostic workup; and nothing here is evidence that twice-yearly whole-body MRI improves health outcomes for anyone. The dashboard records an attributed measurement disclosure with verified screening-policy context—not a reader imaging recommendation, evidence of youthful equivalence, or medical advice. Sleep “Your bedroom should be cold, dark and boring”: the feed’s highest-engagement post of the window is also its most evidence-aligned — the directive is a near-verbatim compression of stimulus control, the AASM-endorsed insomnia therapy whose core instruction is to keep the bedroom for sleep Johnson posted the window’s highest-engagement message (10,810 likes — the feed’s biggest post since the sleep-deviation meme): “Your bedroom should be cold, dark and boring. / If it’s also your office, gym and movie theater, your brain never gets the signal that it’s time to sleep.” (10,810 likes, 309 reposts, 269 replies; October 27, 13:47 UTC). This is the feed’s first standalone sleep-environment directive, and it aligns with the clinical literature more closely than most of what the feed publishes: the middle sentence is a plain-language compression of stimulus control therapy, one of the two core behavioral components of CBT-I, whose defining instruction set — “use the bed/bedroom for sleep and sex only (no reading, watching TV, etc. in bed)” — exists precisely to “extinguish the association between the bed/bedroom and wakefulness” (AASM clinical practice guideline, Edinger et al., J Clin Sleep Med 2021, 10.5664/jcsm.8988: stimulus control is a suggested single-component therapy for chronic insomnia disorder, and multicomponent CBT-I is the strong first-line recommendation). The cold/dark legs trace to the same consensus literature his own sleep-duration guidance already cites: the NSF 2017 consensus identifies a “cold bedroom” among environmental sleep factors, and cool ambient temperature is the standard thermoregulatory guidance for sleep onset, while “dark” maps to light-suppression advice. The boundaries: the post names no study, as always; it is general sleep hygiene rather than an insomnia treatment — and the AASM specifically suggests against sleep hygiene as a stand-alone therapy for chronic insomnia disorder, because environmental advice alone does not treat established insomnia; the “your brain never gets the signal” mechanism is a fair lay rendering of conditioned-arousal theory but is his gloss, not a cited finding; and general-population sleep advice is not a substitute for CBT-I or clinical care for someone with an insomnia disorder. The dashboard records an attributed sleep-environment directive that compresses real, guideline-endorsed behavioral therapy—not a reader insomnia treatment, a clinical protocol, or medical advice. Research claim “Extends the medium lifespan of male mice by 22.5% and 35% in female mice”: the IL-11 relay is a real, landmark Nature paper — but the female figure is wrong in the paper, wrong against Johnson’s own 2024 post, and the relay inherits a quote-post’s framing Johnson quote-posted Ryan Bethencourt’s same-age-mice photo (“the human equivalent of 85… the mouse on the right was given an antibody blocking a single inflammatory protein (IL-11) starting in late middle age”) with: “Extends the medium lifespan of male mice by 22.5% and 35% in female mice. It’s a few years old, I posted about it in 2024. Showed IL-11 as a driver of aging, and tissue inflammation and fibrosis. It climbed up with age, and was linked to fat build up and muscle loss. It is now in Phase II human clinical trials for lung fibrosis.” (1,048 likes, 51 reposts, 43 replies at curation; October 26, 21:41 UTC). The underlying work verifies in full: Widjaja et al., “Inhibition of IL-11 signalling extends mammalian healthspan and lifespan,” Nature, July 17, 2024 (10.1038/s41586-024-07701-9) — Il11 deletion extended lifespan in both sexes (24.9% averaged across genetic-deletion studies), and anti-IL-11 antibody (X203) from 75 weeks until death extended median lifespan 22.5% in males (130.3→159.6 weeks) and 25% in females (117.1→146.4 weeks), with fewer tumours at autopsy, improved metabolism and muscle function, and the ERK–AMPK–mTORC1 framing the post summarizes; the “Phase II human clinical trials for lung fibrosis” leg also verifies — Boehringer Ingelheim announced a Phase IIa trial of first-in-class IL-11 inhibitor BI 765423 in idiopathic pulmonary fibrosis on January 13, 2026, an asset in-licensed from the same Singapore/Duke-NUS lineage as the mouse work (Lassen Therapeutics’ LASN01 anti-IL-11-receptor antibody completed Phase 1/2a in pulmonary fibrosis and thyroid eye disease). But the relay misquotes its own source: the paper’s female figure is 25%, not 35%, and Johnson’s own July 17, 2024 post (“Treatment with anti-IL-11 from 75 weeks of age until death extends the median lifespan of male mice by 22.5% and of female mice by 25%,” with the same 105-week-old mouse photo) quotes it correctly — so the October 26 version degrades against both the paper and his own earlier post, the same class of transcription drift this dashboard recorded on the bone-pressure figure two days earlier. “Medium lifespan” for “median,” and the quote-post’s 85-human-year framing, are Bethencourt’s glosses; the post names no study. Boundaries: mouse antibody dosing and knockout genetics, no human longevity data; the IPF trial tests lung function, not aging endpoints; the photo pair is one representative image, not the survival curves. The dashboard records an attributed research relay with a verified paper and a drifted figure—not evidence for anti-IL-11 in humans, a drug expectancy, or medical advice.

// Reference paths

Move from feed to dossiers

Each route keeps source trails and medical caution visible.
Protocol Health

Habits, Longterm, and Don’ts for measurement loops, sleep consistency, oral care, exercise, and experimental-intervention caution.

 Protocol Longevity

Habits, Longterm, and Don’ts for biomarkers, healthspan basics, critiques, and low-confidence immortality claims.

 Protocol Nutrition

Habits, Longterm, and Don’ts for plant-led meals, Blueprint products, microplastics claims, and metabolic-drug caveats.

 Protocol Sleep

Habits, Longterm, and Don’ts for bedtime discipline, front-loading examples, and metric caution from tweet-backed sources.

 Reference Concepts

39 source-aware glossary entries, including concepts without dedicated wiki pages yet.

 entity Blueprint

Blueprint is bryan-johnson's longevity protocol, product company, and public measurement system. It began as Project Blueprint, an N=1 effort to measure Johnson's organs and biological aging, and later became a consumer

 concept Blueprint Protocol

The Blueprint Protocol is bryan-johnson's closed-loop health system: measure body state, consult scientific evidence, implement interventions, measure again, and update. Johnson treats the body as a system whose organs a

 concept Don't Die

Don't Die is bryan-johnson's community slogan, longevity philosophy, and civilizational frame. The official Don't Die page describes a community “united in defeating all causes of human and planetary death and building a

 concept Biomarker-driven longevity protocols

A biomarker-driven longevity protocol is a health system that treats the body as a measurable control system: collect biomarkers, choose interventions, re-measure, and iterate. project-blueprint is the most visible curre

 Signal Metrics

Inspect source velocity by range, content type, and fallback API state.